Clarient Acquired By GE Healthcare For $580M

Aliso Viejo-based Clarient, a developer of cancer diagnostic tools, is being acquired by GE Healthcare in a deal worth $580M. According to GE Healthcare, which is a unit of General Electric, it will pay $5.00 per common share or $20.00 per preferred share in cash for Clarient. Clarient is a maker of molecular diagnostics tools used to diagnose and characterize cancer. GE Healthcare said the buy will "strongly enhance" its current diagnostic and life science offerings. Calrient was advised by Goldman, Sachs & Co., and Latham & Watkins on the acquisition; GE Healthcare was advised by JP Morgan and Sidley Austin LLP.